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Fortilin interacts with TGF-β1 and prevents TGF-β
receptor activation

1234567890():,;

Decha Pinkaew 1, Erik Martinez-Hackert 2, Wei Jia3, Matthew D. King4, Fei Miao1,6, Nicole R. Enger1,
Runglawan Silakit1, Kota Ramana5, Shi-You Chen3 & Ken Fujise 1 ✉

Fortilin is a 172-amino acid multifunctional protein present in both intra- and extracellular
spaces. Although fortilin binds and regulates various cellular proteins, the biological role of
extracellular fortilin remains unknown. Here we report that fortilin speciﬁcally interacts with
TGF-β1 and prevents it from activating the TGF-β1 signaling pathway. In a standard
immunoprecipitation-western blot assay, fortilin co-immunoprecipitates TGF-β1 and its isoforms. The modiﬁed ELISA assay shows that TGF-β1 remains complexed with fortilin in
human serum. Both bio-layer interferometry and surface plasmon resonance (SPR) reveal
that fortilin directly bind TGF-β1. The SPR analysis also reveals that fortilin and the TGF-β
receptor II (TGFβRII) compete for TGF-β1. Both luciferase and secreted alkaline phosphatase
reporter assays show that fortilin prevents TGF-β1 from activating Smad3 binding to Smadbinding element. Fortilin inhibits the phosphorylation of Smad3 in both quantitative western
blot assays and ELISA. Finally, fortilin inhibits TGFβ-1-induced differentiation of C3H10T1/2
mesenchymal progenitor cells to smooth muscle cells. A computer-assisted virtual docking
reveals that fortilin occupies the pocket of TGF-β1 that is normally occupied by TGFβRII and
that TGF-β1 can bind either fortilin or TGFβRII at any given time. These data support the role
of extracellular fortilin as a negative regulator of the TGF-β1 signaling pathway.
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riginally cloned in 1988 by Gross et al1. as a cytosolic
molecule abundantly expressed in tumor cells, fortilin
remained a protein of unknown function until 2001 when
we2 and others3,4 reported that it protects against apoptosis.
Investigation over the next 20 years revealed that fortilin is a
multi-functional protein implicated in diverse biological processes, including protection against apoptosis2–4, endoplasmic
reticulum stress handling5, cell cycle progression6, reactive oxygen species detoxiﬁcation7, and Ig-E-mediated histamine
release8,9. Fortilin exists in both the cytosol and the nucleus
(cellular fortilin)2 and circulates in the blood10 after being
secreted from the cell (circulating fortilin)11.
In the cell, fortilin exerts its biological activities through its
molecular interaction with its “executioner” proteins. For example, fortilin binds and negatively regulates p53 by preventing p53
from transcriptionally activating its target molecules BAX,
PUMA, and NOXA12,13. In addition, fortilin binds and positively
regulates peroxiredoxin-1, a reactive oxygen species-detoxifying
enzyme, by preventing it from being inactivated by Mst1 kinase7.
Moreover, fortilin binds and stabilizes the myeloid cell leukemia
protein-1 (MCL1), a Bcl-2 family member anti-apoptotic molecule, thereby supporting the survival of myeloid cells14,15. Finally,
fortilin binds and inhibits the inositol-requiring enzyme 1 alpha
(IRE1α), an endoplasmic reticulum (ER) stress sensor5.
We and others have shown that fortilin is secreted from the
cell10 via the non-classical pathway11 and circulates in the blood
of humans and mice10. However, the biological activity of circulating fortilin has been poorly understood. Herein we report
that fortilin physically binds TGF-β1, functionally inhibits the
TGF-β1 signaling pathway, and prevents mesenchymal progenitor cells from differentiating into vascular smooth
muscle cells. We propose that extracellular fortilin is an inhibitor
of TGF-β1.
Results
Co-immunoprecipitation (Co-IP) assays showed that fortilin
binds TGF-β1. To test whether fortilin physically interacts with
TGF-β1, we performed in vitro Co-IP assays using recombinant
human fortilin (rh-fortilin) and TGF-β1 (rh-TGF-β1) proteins.
We equally divided the reaction mixture containing rh-fortilin, rhTGF-β1, rh-p53, and rh-N-Ribosyldihydronicotinamide:Quinone
Reductase 2 (rh-NQO2) into two microfuge tubes (Fig. 1a,
INPUT; Supplementary Fig. 4 or Fig. S4 hereafter). We added
rabbit IgG to the ﬁrst tube and rabbit monoclonal anti-fortilin
antibody (α-fortilin mAb) to the second tube. After incubation
and extensive washing, the immune complex pulled down with
anti-rabbit-IgG magnetic beads was eluted into SDS-loading buffer. The system was functioning appropriately, as fortilin was able
to co-immunoprecipitate p53, a known fortilin-interacting
protein12 (Fig. 1a, lane 3, row c). Washing was sufﬁciently stringent to prevent fortilin from nonspeciﬁcally binding NQO2, a
protein that is known not to interact with fortilin7
(Fig. 1a, lane 3, row d). Using this protocol, the presence of coimmunoprecipitated TGF-β1 was evaluated by the same western
blot analysis. We found that α-fortilin mAb (Fig. 1a, lane 3, row a),
but not IgG (Fig. 1a, lane 2, row a), immunoprecipitated fortilin
and that TGF-β1 was successfully co-immunoprecipitated in the
presence of fortilin (Fig. 1a, lane 3, row b) but not in its absence
(Fig. 1a, lane 2, row b), suggesting that fortilin and TGF-β1 speciﬁcally interact with each other.
To test whether fortilin also interacts with other isoforms of
TGF-β (TGF-β2 and TGF-β3), we performed the same Co-IP
experiment using rh-TGF-β2 and rh-TGF-β3. We found that αfortilin mAb (Fig. 1b, lane 3, row a; lane 6, row a; Figs. S5, S6), but
not IgG (Fig. 1b, lane 2, row a; lane 5, row a),
2

immunoprecipitated fortilin and that fortilin was capable of coimmunoprecipitating both TGF-β2 (Fig. 1b, lane 3, row b) and
TGF-β3 (Fig. 1b, lane 6, row b) but not NQO2 (Fig. 1b, lane 3,
row c; lane 6, row c). These data suggest that fortilin speciﬁcally
interacts with TGF-β1, TGF-β2, and TGF-β3.
Fortilin circulates in the mouse and human blood at the serum
concentrations of 2.17 ± 0.58 nM (biological replicates (N) = 30)
and 3.41 ± 2.07 nM (N = 63), respectively, as we previously
reported10. To assess the relative contribution of TGF-β1, TGFβ2, and TGF-β3 to the formation of a complex with fortilin in the
blood, we measured their serum concentrations using a multiplex
assay system (MILLIPLEX™ MAP TGFβ Magnetic Bead 3 Plex
Kit, Millipore Sigma, Burlington, MA). We found the concentrations of TGF-β1, TGF-β2, and TGF-β3 to be 10.5 ± 2.1, 1.2 ± 0.06,
and <0.023 (lower than the detection limit) nM, respectively
(N = 15 each) (Fig. S1a), suggesting that the fortilin-TGF-β1
interaction represents the majority of fortilin-TGF-β interactions
in the blood. Similar results have been reported for normal
human plasma as well16,17. We therefore focused on the fortilinTGF-β1 interaction in the remainder of the project.
To determine if fortilin and TGF-β1 form a complex in vivo in
normal human circulation, we obtained de-identiﬁed platelet-rich
plasma from the University of Washington Blood Bank and
generated serum by adding thrombin to the plasma. We divided
the serum into two portions and, from one portion, immunodepleted
both fortilin and TGF-β1 using magnetic beads coated with either αfortilin-mAb or α-TGF-β-mAb (SeraTGF-β1-, fortilin-). We then
subjected both the original sera (SeraTGF-β1+, fortilin+) and SeraTGFβ1-, fortilin- to three distinct ELISA systems (Fig. 1c–e). We ﬁrst
performed standard TGF-β1 ELISA using α-TGF-β1 capturing Ab
and α-TGF-β1 detecting Ab. We found that SeraTGF-β1+, fortilin+
contained ~2.5 time more TGF-β1 than SeraTGF-β1-, fortilin(SeraTGF-β1+, fortilin+ vs. SeraTGF-β1-, fortilin- = 1.58 ± 0.078 vs.
0.62 ± 0.017 [Absorbance 450 or Abs450]) (Fig. 1c, columns 1 vs.
2). We then performed standard fortilin ELISA as described
previously10 using α-fortilin capturing Ab and α-fortilin detecting
Ab. We found that SeraTGF-β1+, fortilin+ contained ~10 times more
fortilin than SeraTGF-β1-, fortilin- (SeraTGF-β1+, fortilin+ vs. SeraTGF-β1, fortilin- = 1.21 ± 0.042 vs. 0.12 ± 0.029 Abs ) (Fig. 1d, columns 1 vs.
450
2). When taken together (Fig. 1c, d), these data suggest that TGF-β1
and fortilin ELISA’s were capable of speciﬁcally detecting TGF-β1
and fortilin in SeraTGF-β1+, fortilin+, respectively.
We then subjected these sera to the modiﬁed ELISA using αTGF-β1 capturing Ab and α-fortilin detecting Ab (Fig. 1e, upper
panel). We found that SeraTGF-β1+, fortilin+ yielded ~10 times
more signals than did SeraTGF-β1-, fortilin- (SeraTGF-β1+, fortilin+ vs.
vs.
0.08 ± 0.01
Abs450)
SeraTGF-β1-, fortilin- = 0.77 ± 0.049
(Fig. 1e, columns 1 vs. 2), showing that TGF-β1 captured by αTGF-β1 capturing Ab was bound to fortilin, which was in turn
detected by α-fortilin detecting Ab. These data suggest that
fortilin and TGF-β1 form a complex in vivo in normal
human sera.
Finally, we tested if fortilin could be co-puriﬁed by afﬁnity
column puriﬁcation of TGF-β1 (Fig. S1b). After packing and
equilibrating a gravity chromatography column with agarose
beads conjugated to α-TGF-β1 antibody (Santa Cruz Biotechnology, Dallas TX, USA) (Figs. S1b, 1), we loaded it with SeraTGFβ1+, fortilin+ (Figs. S1b, 2), extensively washed it with Wash Buffer
(phosphate-buffered saline (PBS)) (Figs. S1b, 3), and eluted the
bound proteins by adding Elution Buffer (0.1 M Glycine HCl)
(Figs. S1b, 4). We subjected the input (SeraTGF-β1+, fortilin+,
Fig. S1c, INPUT), ﬂow-through (Fig. S1c, FT), wash ﬂowthroughs (Fig. S1c, WASH-1, -2, -4, and -5), and eluate (Fig. S1c,
ELUATE) to western blot analysis using α-TGF-β1 and α-fortilin
Abs. Strikingly, we found that the eluant contained both fortilin
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Fig. 1 Fortilin and TGF-βs speciﬁcally interact with each other. IP, immunoprecipitation; IB, immunoblot; α-Flag, anti-FLAG antibody; α-TGF-β1, anti-TGFβ1 antibody; α-His6, anti-hexa-histidine antibody; ELISA, enzyme-linked immunosorbent assay; TMB, 3,3’,5,5’-tetramethylbenzidine; HRP, horse-radish
peroxidase; Capture, capturing antibody; Detection, detecting antibody; SeraTGF-β1+, fortilin+, sera generated from platelet-rich plasma; SeraTGF-β1-, fortilin-,
SeraTGF-β1+, fortilin+ immunodepleted of both fortilin and TGF-β1; BSA, bovine serum albumin; Ab, antibody; ABS450, absorbance at 450 nm; Data points,
means ± SD; statistical analyses performed using ANOVA with Fisher’s multiple comparison; ****P < 0.001. a Fortilin interacts with TGF-β1. Recombinant
Flag-tagged fortilin, TGF-β1, Flag-tagged p53, and His6-tagged NQO2 were incubated in binding buffer. α-fortilin antibody was used to immunoprecipitate
fortilin, and immune complexes were resolved in SDS-PAGE and blotted onto a nitrocellulose membrane. Immunoblot analyses using α-TGF-β1, α-Flag, and
α-His6 antibodies showed that fortilin co-immunoprecipitated TGF-β1 and p53 but not NQO2. Fortilin is known to interact with p53 but not with NQO2.
INPUT represented 10% of the total reaction mixture used for IP. b Fortilin interacts with TGF-β2 and -β3. Recombinant Flag-tagged fortilin, TGF-β2 or TGFβ3, and His6-tagged NQO2 were incubated in binding buffer. α-fortilin antibody was used to immunoprecipitate fortilin, and immune complexes were
resolved in SDS-PAGE and blotted onto a nitrocellulose membrane. Immunoblot analyses using α-Flag, α-TGF-β, and α-His6 antibodies showed that fortilin
co-immunoprecipitated TGF-β2 and -β3, but not NQO2. INPUT represented 10% of the total reaction mixture used for IP. c Detection of TGF-β1 in normal
human serum. The TGF-β1 ELISA that used α-TGF-β1 capturing and detecting Abs showed high TGF-β1 levels in SeraTGF-β1+, fortilin+ (column 1) compared
with those in SeraTGF-β1-, fortilin- (column 2). N = 3. d Detection of fortilin in normal human serum. The in-house fortilin ELISA that used α-fortilin capturing
and detecting Abs showed high fortilin levels in SeraTGF-β1+, fortilin+ (column 1) compared with those in SeraTGF-β1-, fortilin- (column 2). N = 3. e Detection of
the fortilin-TGF-β1 interaction in normal human serum. The modiﬁed ELISA system that used α-TGF-β1 capturing and α-fortilin detecting Abs yielded a
robust signal in SeraTGF-β1+, fortilin+ (column 1) compared with those in SeraTGF-β1-, fortilin- (column 2). N = 3.

and TGF-β1 (Fig. S1c, ELUATE; Fig. S8), suggesting that afﬁnitypuriﬁed TGF-β1 was bound to fortilin and that fortilin and TGFβ1 form a complex in vivo in normal human sera.
Bio-layer interferometry (BLI) showed that fortilin binds TGFβ1. The above Co-IP, ELISA, and column experiments suggested
that fortilin speciﬁcally interacts with TGF-β1 (Figs. 1, S1c). Next,
we investigated binding between the two proteins using both BLI
and surface plasmon resonance (SPR). For BLI assays, biotinylated rh-fortilin was immobilized on streptavidin-coated biosensors (ForteBio, Menlo Park, CA) and washed in PBS for 30 s.
Various concentrations of rh-TGF-β1 were applied to the biosensors for 180 s to evaluate the association between the two
proteins before rh-TGF-β1 solution was replaced by PBS for 180 s
to evaluate their dissociation. Analyses of the binding data sets

conducted using Blitz analysis software (Forte Bio) revealed an
equilibrium dissociation constant (Kd) of 94.5 nM, suggesting that
both proteins interacted with each other speciﬁcally and at a
medium intensity (Fig. 2a). TGF-β1 is synthesized as a precursor
molecule comprising a signal peptide, LAP, and a mature TGF-β1
polypeptide18. Using the same methods, we tested if rh-fortilin
interacted with recombinant human latency-associated-peptide
(LAP)-TGF-β1 molecule. We found that the binding of fortilin to
the LAP-TGF-β1 protein was weaker than that of fortilin to TGFβ1, at 0.93 µM (Fig. S1d).
SPR showed that fortilin binds TGF-β1. For SPR assays, we
cross-linked rh-fortilin on an SPR sensor chip and injected rhTGF-β1 at increasing concentrations (0 to 200 nM) (Figs. 2b,
S2a). We detected speciﬁc binding between the two proteins
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Fig. 2 Both BLI and SPR show the speciﬁc interaction between fortilin and TGF-β1. BLI, bio-layer interferometry; Kd, dissociation constant; SPR, surface
plasmon resonance; His6-fortilin, hexa-his-tagged recombinant fortilin; TGFβRIIFc, the ligand-binding segment of the TGF-β receptor II conjugated to the Fc
portion of the IgG. a BLI showed the speciﬁc binding of fortilin to TGF-β1 at Kd of 94.5 nM. b SPR showed that fortilin binds TGF-β1 at Kd of 210.5 nM. c
After fortilin was conjugated to the SPR chip surface, TGFβRIIFc mixed with various concentrations of TGF-β1 was injected onto the chip surface to evaluate
the binding of fortilin to TGF-β1 in the presence of TGFβRII. There was dose-dependent disruption by TGFβRII of the fortilin-TGF-β1 interaction. Because
fortilin did not bind TGFβRIIFc (Fig. S2b), the data suggest that fortilin and TGFβRII competitively bind TGF-β1.

regardless of the location and nature of epitope tags, as indicated
by the concentration-dependent increase in response units
(Figs. 2b, S2a). To obtain the dissociation constant at equilibrium,
we ﬁtted the SPR response at steady state of TGF-β1 binding to
N-terminal (Fig. 2b) His-tagged fortilin using the one site total
binding model as implemented in GraphPad. We calculated a Kd
of 210 nM, a value that is consistent with a medium afﬁnity
protein–protein interaction and similar to that from the
BLI assay.
To gain greater molecular insights into the fortilin-TGF-β1
interaction, we used an SPR-based co-binding/inhibition assay
that enables coarse epitope mapping (Fig. 2c)19. In this assay, a
constant concentration of analyte (TGF-β1) was pre-incubated
with increasing concentrations of the ligand-binding domain of
the TGF-β1 receptor TGFβRII fused to IgG1 Fc (TGFβRII-Fc), a
known interacting partner of TGF-β1. These TGFβ1–TGFβRII-Fc
mixtures were injected onto a chip that had been cross-linked
with fortilin. If TGFβRII-Fc and fortilin interact with the same
epitope on TGF-β1, then we expected that higher TGFβRII-Fc
concentrations would reduce the TGF-β1-dependent SPR signal.
However, if TGFβRII-Fc and fortilin interact with different TGFβ1 surfaces, then we expected that higher TGFβRII-Fc concentrations would lead to an increased TGF-β1 SPR signal.
Importantly, we found that TGFβRII-Fc reduced the TGF-β1
signal in a concentration-dependent manner, indicating that
TGFβRII-Fc prevented binding of TGF-β1 to fortilin (Fig. 2c).
IgG Fc alone (Fc) did not prevent TGF-β1 from binding fortilin
(Fig. S2b, TGFβ1 + Fc), and Fc did not bind fortilin (Fig. S2b, Fc
alone). These data are consistent with a model in which fortilin
and TGFβRII contact the same surface on TGF-β1, thus
providing direct evidence for a mechanism of TGF-β1 inhibition
by fortilin.
4

Fortilin prevents TGF-β1 from activating the Smad-binding
element (SBE) in the cell. The above data (Figs. 1, 2), when taken
together, suggested that fortilin prevents TGF-β1 from ligating
and activating TGFβRII, but we still did not know if this physical
interaction has biological and functional signiﬁcance. To test
whether fortilin prevents TGF-β1 from activating the TGF-β1Smad pathway in the cell, we ﬁrst expressed strep-tagged fortilin
(strep-tag-fortilin) and luciferase (strep-tag-luciferase) using
293T cells, puriﬁed them in the sterile condition, characterized
them, and found that they were of appropriate sizes and acceptable purity without degradation (Fig. S3a; Figs. S9, S10). We then
transiently transfected HEK293 cells with both the SBE-luciferase
plasmid and the Renilla luciferase plasmid (the latter to evaluate
transfection efﬁciency), treated them with TGF-β1 (1 nM) in the
presence and absence of strep-tag-fortilin (3 nM), and subjected
the cells to the dual luciferase assay as described in the Methods.
Fortilin signiﬁcantly decreased the TGF-β1-induced activation of
SBE (luciferase activities; fortilin (−) vs. fortilin (+) = lanes 2 vs.
4 = 8.1 ± 0.2 vs. 5.4 ± 0.5 arbitrary units (A.U.), P < 0.001, N = 4
each) (Fig. 3a).
Next, we used the MFB-F11 cell line to validate these ﬁndings
using a different cell system. The cell line was originally generated
by stably transfecting mouse embryonic ﬁbroblasts from Tgfb1−/−
mice with a construct in which the 12 CAGA boxes—Smad3/
Smad4 binding sequences present in the human plasminogen
activator inhibitor-1 gene20—are fused to a secreted alkaline
phosphatase (SEAP) reporter gene21,22. This cell line has been
shown to respond to TGF-β1 in a linear fashion from 1 pg/mL to
10 ng/mL (0.04–400 pM), which is an extremely wide dynamic
range (ref. 21 and Fig. S3b). We ﬁrst stimulated the MFB-F11 cells
with 156 pM (2 ng/mL) of recombinant TGF-β1 and found that
the SEAP activity increased 11.4-fold (Fig. 3b, lanes 1 vs. 2).
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Fig. 3 The luciferase assay shows that fortilin blocks TGF-β1-induced activation of the Smad2/3 binding element. strep-tag-fortilin, recombinant fortilin
with strep-tag at its N-terminus; strep-tag-luciferase, recombinant luciferase with strep-tag at its N-terminus, used as the control; α-TGF-β1 mAb,
neutralizing anti-TGF-β1 monoclonal antibody (1.25 µg/mL or 8.33 nM); HEK, human embryonic kidney cells; SBE-Luc, a vector containing the Smad2/3
binding element fused to the luciferase cDNA; A.U., arbitrary unit; SBE-SEAP, a vector containing the Smad2/3 binding element fused to the secreted
embryonic alkaline phosphatase cDNA; MFB-F11SBE-SEAP cells, immortalized mouse embryonic ﬁbroblasts from Tgfb1−/− mice that stably harbor the SBESEAP construct; data points, means ± SD; statistical analyses performed using ANOVA with Fisher’s multiple comparison; N, the number of biological
replicates; NS, not statistically signiﬁcant; ****P < 0.001. a Fortilin prevented TGF-β1 from activating the SBE in HEK293SBE-Luc cells; 1 nM TGF-β1 and 1 nM
strep-tag-fortilin were used. N = 4. b Fortilin, but not luciferase control protein, dose-dependently blocked TGF-β1-induced SBE activation in the MFBF11SBE-SEAP cells; 156 pM TGF-β1 was used to stimulate the cells. Moreover, 19.5 (low dose, +) and 195 (high dose, ++) nM strep-tag-fortilin or strep-tagluciferase were used to block TGF-β1-induced SBE activation. N = 6.

Addition of strep-tag-fortilin (Fig. 3b, lanes 3 and 4), but not
strep-tag-luciferase (Fig. 3b, lanes 5 and 6), prevented TGF-β1
from activating its signaling pathway in a dose-dependent fashion
(Fig. 3b, lanes 2 vs. 3 vs. 4 = 11.4, 8.1, and 6.3 A.U. for 0, 19.5, and
195 nM fortilin, respectively, P < 0.001 by one-way analysis of
variance (ANOVA), Fisher pairwise comparisons). These data
suggest that the functional signiﬁcance of fortilin binding to TGFβ1 is the inhibition of the TGF-β1 signaling pathway.
Fortilin prevents TGF-β1 from phosphorylating Smad3. To
further validate that fortilin prevents TGF-β1 from activating the
TGF-β1 pathway, we evaluated the status of Smad3 phosphorylation (P-Smad3) in TGF-β1-stimulated MFB-F11SBE-SEAP cells
in the presence and absence of fortilin, using quantitative western
blot analysis (Fig. 4a–c; Fig. S7), where P-Smad3 signals were
normalized to either total proteins loaded (Fig. 4b) or total Smad3
(Fig. 4c). In the absence of TGF-β1, neither recombinant fortilin
(strep-tag-fortilin) nor its control recombinant luciferase (streptag-luciferase) induced Smad3 phosphorylation (Fig. 4a, lanes
1–6; Fig. 4b, lanes 1–3; Fig. 4c, lanes 1–3). TGF-β1, but not TGFβ1 in the presence of anti-TGF-β1 antibody, induced the phosphorylation of Smad3 (Fig. 4a, lanes 7 & 8 vs. 13 & 14; Fig. 4b,
lanes 4 vs. 7; Fig. 4c, lanes 4 vs. 7). In this system, recombinant
fortilin, but not control recombinant luciferase, decreased the
TGF-β1-induced phosphorylation of Smad3 (Fig. 4a, lanes 9 & 10
vs. 11 & 12; Fig. 4b, lanes 5 vs. 6; Fig. 4c, lanes 5 vs. 6). To further
validate this ﬁnding, we subjected the cell lysates from the same
experiment to ELISA of P-Smad3. Consistently, the data showed

that TGF-β1-induced phosphorylation of Smad3 was inhibited by
recombinant fortilin (Fig. 4d, lanes 4 vs. 5) but not by recombinant luciferase (Fig. 4d, lanes 4 vs. 6).
Fortilin inhibits TGF-β1-induced smooth muscle marker
expression in C3H10T1/2 cells. In atherosclerosis, smooth
muscle cells (SMCs) accumulate in the intimal space, produce
extracellular matrix (ECM), and contribute to the expansion of
the plaque23. There are several theories about the source of
intimal SMCs: (i) dedifferentiated medial SMC, (ii) adventitial
progenitor cells, (iii) medial progenitor cells, or (iv) bone marrow
progenitor cells23. TGF-β1 has been shown to play an important
role in both (i) differentiation of progenitor cells to SMCs and (ii)
maturation of proliferative SMCs to contractile and quiescent
SMCs23. To investigate the role of fortilin in TGF-β1-induced
differentiation of progenitor cells to SMCs, we evaluated the
mRNA expression of SMC differentiation markers CNN1
(Fig. 5a)24, α-SMA (Fig. 5b)25, and SMA22α (Fig. 5c)25 in
C3H10T1/2 cells exposed to TGF-β1, fortilin, or their mixture.
The C3H10T1/2 cell line, originally established from C3H mouse
embryos26, displays attribute similar to those of mesenchymal
stem cells and, when treated with TGF-β1, cells differentiate to
become vascular SMCs27. C3H10T1/2 cells express no epithelial
markers without stimulation28. Stimulation by TGF-β1 (Fig. 5a–c,
lanes 1 vs. 3), but not by fortilin (Fig. 5a–c, lanes 1 vs. 2), dramatically enhanced mRNA expression of the differentiation
markers as determined by quantitative real-time PCR assays.
Strikingly, recombinant fortilin (strep-tag-fortilin) abrogated
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Fig. 4 Quantitative western blots and ELISA show that fortilin blocks TGF-β1-induced phosphorylation of Smad3. SBE-SEAP, a vector containing the
Smad2/3 binding element fused to the secreted embryonic alkaline phosphatase cDNA; MFB-F11SBE-SEAP cells, immortalized mouse embryonic ﬁbroblasts
from Tgfb1−/− mice that stably harbor the SBE-SEAP construct; strep-tag-fortilin, recombinant fortilin with strep-tag at its N-terminus (19.5 nM); strep-tagluciferase, recombinant luciferase with strep-tag at its N-terminus, used as the control (19.5 nM); α-TGF-β1 mAb, neutralizing α-TGF-β1 monoclonal
antibody (1.25 µg/mL or 8.33 nM); IB, immunoblot; α-P-Smad3, anti-phosphorylated Smad3 antibody; α-Smad3, anti-Smad3 antibody; TCE, 2,2,2trichloroethanol; A.U., arbitrary unit. a Western blot analysis using α-P-Smad3 and α-Smad3 and total protein visualization by TCE. b, c Quantiﬁcation of
P-Smad3, normalized to total proteins (b) and total Smad3 (c), showing that fortilin, but not luciferase control protein, prevented TGF-β1 from
phosphorylating Smad3. d ELISA of P-Smad3 on the lysates from MFB-F11SBE-SEAP cells also showed that fortilin, but not luciferase control protein,
prevented TGF-β1 from phosphorylating Smad3.

TGF-β1-induced upregulation of the SMC differentiation markers compared with the control (Fig. 5a–c, TGF-β1 (lane 3) vs.
TGF-β1 + fortilin (lane 4)). These data suggest that fortilin prevents TGF-β1 from differentiating C3H10T1/2 progenitor cells to
SMCs and that fortilin is an inhibitor of TGF-β1.
Structural basis for inhibition of the TGF-β1 pathway by fortilin. Because it interacts with TGF-β1, TGF-β2, and TGF-β3
(Fig. 1), fortilin is likely to bind the conserved segments of these
three isoforms. We ﬁrst aligned the isoforms and found that
TGF-β1 and TGF-β2 are 71% identical, TGF-β1 and TGF-β3 are
77% identical, and TGF-β2 and TGF-β3 are 79% identical. There
are eight highly conserved segments among the three proteins
(Fig. 6a, segments a–h). In addition, Radaev et al. reported cocrystallization of TGF-β1 and TGFβRII (Protein Data Base [PDB]
ID: 3KFD) and found that the interaction between these two
proteins involves the following ﬁve TGF-β1 residues: Arg25,
His34, Tyr91, Gly93, and Arg94 (Fig. 6a, +)29. They also noted that
the interaction between TGF-β2 and TGFβRII is much weaker
than those between TGF-β1/3 and TGFβRII based on SPR
analyses29. Hart et al. performed co-crystallization of TGF-β3 and
6

TGFβRII (PDB: 1KTZ) and identiﬁed 10 amino acids residues
located at the TGF-β3-TGRβRII interface: Arg25, Lys31, Trp32,
His34, Lys37, Tyr90, Tyr91, Gly93, Arg94, and Thr95 (Fig. 6a, *)30.
Because ﬁve amino acids (Arg25, His34, Tyr91, Gly93, and Arg94)
of TGF-β1/3 are common between the TGF-β1-TGFβRII and
TGF-β3-TGFβRII interfaces and because our SPR data suggested
that fortilin binds TGF-β1 through the TGF-β1-TGFβRII interface (Fig. 2c), it is likely that fortilin interacts with TGF-β1
through one of these ﬁve amino acids. Arg25 and His34 of TGFβ1/3 within the highly conserved segments a–c represent the most
promising amino acids participating in the interaction with fortilin (Fig. 6a).
To evaluate how fortilin and TGFβRII structurally compete for
TGF-β1, we performed computational modeling of dimerized
TGF-β1 (PDB ID: 3KFD) and either fortilin (PBD ID: 2HR9) or
TGFβRII (PDB ID: 5TY4) in ClusPro31–34. We found that fortilin
and TGFβRII occupy the same spatial location in relation to
dimerized TGF-β1, suggesting that either fortilin or TGFβRII, but
not both, can bind dimerized TGF-β1 at a given time (Fig. 6b,
blue, TGFβRII; red, TGF-β1 dimer; green, fortilin). We then
evaluated the nature of the molecular interaction between the
fortilin and TGF-β1 dimer. We found that Glu12, Glu138, Asp44,
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of the SBE in both luciferase assays in HEK293 cells (Fig. 3a) and
SEAP assays in MFB-F11 cells (Fig. 3b), and blocked the
phosphorylation of Smad3 as determined by both western blot
analysis (Fig. 4a–c) and ELISA (Fig. 4d). Fortilin also prevented
TGF-β1 from differentiating C3H10T1/2 mesenchymal pluripotent cells into SMCs (Fig. 5). When taken together with prior
crystallographic studies, the computational docking study results
(Fig. 6b–d) and analyses of TGF-β amino acid sequences (Fig. 6a)
also support the fortilin-TGF-β1 interaction. Our results suggest
that fortilin speciﬁcally binds TGF-β1 and prevents it from
ligating and activating TGFβRII (Fig. 6e), although further
investigation is necessary to determine the role of the fortilinTGF-β1 interaction in human diseases.

Fig. 5 Fortilin inhibits TGF-β1-induced differentiation of the C3H10T1/2
mesenchymal progenitor cells. CNN1, Calponin 1; α-SMA, alpha-smooth
muscle actin; SMA22α, smooth muscle protein 22α; A.U. arbitrary unit;
Data points, means ± SD; N, the number of biological replicates; *P < 0.05,
***P < 0.005; ****P < 0.001. C3H10T1/2 cells were starved with DMEM
containing 0.1% fetal bovine serum for 48 h followed by incubation with
fortilin (0.5 µg/mL), TGF-β1 (1 ng/mL), or their mixture for 8 h. Untreated
cells were used as the negative control. Quantitative real-time PCR was
performed (N = 3) to determine mRNA expression of CNN1 (a), α-SMA
(b), and SMA22α (c) in C3H10T1/2 cells. CYP was used the internal
reference. Fortilin inhibited TGF-β1-induced expression of the smooth
muscle cell differentiation marker proteins (CNN1, α-SMA, and SMA22α) in
C3H10T1/2 cells.

and Asp45 of fortilin created hydrogen bonding with Arg25,
Trp30, Lys13, and Gly46 of one of the TGF-β1 molecules (A),
respectively (Fig. 6c). Intriguingly, Arg25 of TGF-β1/3 has been
shown to interface with TGFβRII in crystallographic studies29,30
(Fig. 6a, * & +). We also found that the hydrophobic region of
the binding interface was formed by (a) Ile43, Leu47, and Ile48 of
fortilin; (b) Phe43, Leu45, Val79, and Pro80 of the ﬁrst TGF-β1
molecule (A); and (c) Ala72, Ala73, and Ala74 of the second TGFβ1 molecule (B) (Fig. 6d), suggesting that the thermodynamic
stability of the fortilin-TGF-β1 interaction is attained by both
hydrogen bonding and hydrophobic interaction between the two
molecules.
In conclusion, we showed that fortilin speciﬁcally interacts with
TGF-β1 using Co-IP-western blot analysis (Fig. 1a), the modiﬁed
ELISA system (Fig. 1e), the column afﬁnity co-puriﬁcation assays
(Figs. S1b, c), BLI analysis (Fig. 2a), and SPR assays (Fig. 2b). The
binding of fortilin to TGF-β1 prevented it from ligating TGFβRII
as shown by SPR (Fig. 2c), inhibited TGF-β1-induced activation

Discussion
The most substantial ﬁndings of this study are the speciﬁc physical interaction between fortilin and TGF-β1 and elucidation of
the biological signiﬁcance of this interaction, namely that fortilin
negatively regulates the ability of TGF-β1 to activate its canonical
pathway through TGFβRII.
Because the serum concentration of TGF-β1 is drastically
higher than those of TGF-β2 and TGF-β3 (Fig. S1a), we focused
on the interaction between fortilin and TGF-β1 in the current
work. Although the fortilin-TGF-β1 interaction may represent
the majority of fortilin-TGF-β interactions in the blood, further
investigation is called for to characterize and elucidate the biological signiﬁcance of the fortilin-TGF-β2/3 interaction.
Although fortilin speciﬁcally binds TGF-β1, the fortilin-TGFβ1 interaction is weaker than the interaction between TGF-β1 and
TGFβRII. As we previously reported, the Kd between TGF-β1 and
TGFβRII is 1.49 nM35, whereas the Kd of the TGF-β1-fortilin
interaction is 94.5–210.5 nM (Fig. 2a, b). This suggests that once
TGF-β1 binds TGFβRII, fortilin is not capable of disrupting the
ligation, which is also consistent with the dose-dependent disruption by TGFβRII of the fortilin-TGF-β1 interaction shown in
Fig. 2c. Fortilin may interfere with the biological activities of
TGF-β1 by binding and trapping it before it reaches TGFβRII, its
receptor.
It has been established that TGF-β binds directly to TGFβRII,
which is a constitutional kinase. Bound TGF-β is then recognized
by TGFβRI, which is recruited to the TGF-β-TGFβRII complex
and becomes phosphorylated and activated by TGFβRII. Activated TGFβRI in turn phosphorylates and activates Smad3. In
other words, Smad3 is phosphorylated only when TGFβRI is
recruited to the TGF-β-TGFβRII complex and activated by
phosphorylation36–39. Our data showing that fortilin inhibits
TGF-β1-induced Smad3 phosphorylation (Fig. 4) suggest that
fortilin inhibits the recruitment of TGFβRI to TGFβRII by preventing TGF-β1 from ligating TGFβRII but not by preventing the
formed TGF-β1-TGFβRII complex from recruiting TGFβR1, as
the TGF-β1-TGFβRII interaction is stronger than the TGF-β1fortilin interaction (1.49 nM35 versus 94.5–210.5 nM, Fig. 2a, b).
TGF-β1 also interacts with many molecules other than fortilin,
as reported in the literature. These TGF-β1-interacting proteins
are localized in (a) the blood—thrombospondin-1 (THBS1)40–42,
α2-macroglobulin (A2M)40–42, pregnancy zone protein (PZP)43,
β-amyloid1-4043, and follistatin-like-1 (FSTL1)43; (b) the extracellular matrix—LAP18,44, asporin45, decorin46, ﬁbrinogen47,
ﬁbrinogen β-chain (FGB)48, biglycan49, ﬁbromodulin49,
lumican49, collagen type 1α1 (COL1A1)50, and collagen type 2α1
(COL2A1)51; and (c) the plasma membrane—endoglin52–56,
activin A receptor-like type 157,58, and FSTL159,60.
These TGF-β1-interacting proteins have been demonstrated to
have diverse biological impacts on TGF-β1 signaling. They can be
either positive, as with THBS140–42, ﬁbrinogen47, FGB48,
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Fig. 6 Fortilin occupies the binding space for TGF1-β1 that is normally occupied by TGFβRII. +, amino acid residues interfacing between TGF-β1 and
TGFBRII; *, amino acid residues interfacing between TGF-β3 and TGFBRII; Identities, the amino acid residues of TGF-β2 and TGF-β3 that are identical to
those of TGF-β1; ECS, extracellular space; PM, plasma membrane; P, phosphorylated amino acid residue; TGFβRI, TGF-β1 receptor I; TGFβRII, TGF-β1
receptor II. a Sequence alignment of TGF-β1, -β2, and -β3. Five amino acids (Arg25, His34, Tyr91, Gly93, and Arg94) of TGF-β1 (+) and 10 amino acids
(Arg25, Lys31, Trp32, His34, Lys37, Tyr90, Tyr91, Gly93, Arg94, and Thr95) of TGF-β3 (*) interface with TGFβRII according to the prior co-crystallization
studies. b Computational modeling of dimerized TGF-β1 and either fortilin or TGFβRII. Fortilin (green) and TGFβRII (blue) occupy the same spatial location
in relation to dimerized TGF-β1 (red, chains A and B) and either fortilin or TGFβRII, but not both, can bind dimerized TGF-β1 at a given time. Fortilin and
TGFβRII are depicted in an overlaid fashion. The small open circles denote arginine (Arg) residues. c Structural basis of the fortilin-TGF-β1 interaction—
hydrogen bonding. Glu12, Glu138, Asp44, and Asp45 of fortilin create hydrogen bonding with Arg25, Trp30, Lys13, and Gly46 of one of the TGF-β1 molecules
(chain A). d Structural basis of the fortilin-TGF-β1 interaction—hydrophobic binding surface. The hydrophobic region of the binding interface is formed by
(a) Ile43, Leu47, and Ile48 of fortilin, (b) Phe43, Leu45, Val79, and Pro80 of the ﬁrst TGF-β1 molecule (chain A), and (c) Ala72, Ala73, and Ala74 of the second
TGF-β1 molecule (chain B). e The role of fortilin in the regulation of the TGF-β1 pathway. TGFβRII, when ligated by TGF-β1, recruits and phosphorylates
TGFβRI, which in turn phosphorylates Smad2/3. Phosphorylated Smad2/3 enters the nucleus and activates TGF-β1 target genes (left panel). Fortilin binds
TGF-β1 and prevents TGF-β1 from ligating and activating TGF-β1 receptors (right panel).

endoglin52–56, activin A receptor-like type 158, and FSTL159,60 or
(b) negative, as with asporin45, decorin46, A2M61, and PZP43. On
the other hand, TGF-β1 has been shown to impact the biological
activity of TGF-β1-binding proteins either positively or negatively. For example, TGF-β1 directly binds the 40-residue Aβ
peptide (Aβ1-40), facilitates the oligomerization of Aβ1-40, and
enhances Aβ1-40-mediated toxicity in PC12 cells62. TGF-β1 binds
the 50–55 kDa secreted protein FSTL1 and prevents it from
interacting with its putative transmembrane receptor (discointeracting protein 2)59. The biological signiﬁcance of the TGF-β1
interaction with biglycan49, ﬁbromodulin49, lumican49,
COL1A150, and COL2A151 remains unknown.
Fortilin has no sequence similarity to any of the above TGF-β1interacting proteins, and it possesses several unique attributes that
they do not have. First, fortilin is present not only in the
8

extracellular space where it interacts with TGF-β1 but also in the
nucleus, ER, and cytosol where it interacts with p5312, IRE1α5,
and MCL115, respectively. Second, fortilin is a multi-functional
protein: in addition to binding and inhibiting TGF-β1, fortilin
protects cells against apoptosis by (i) binding and inhibiting the
pro-apoptotic and tumor suppressor protein p5312, (ii) binding
and protecting against degradation of the anti-apoptotic Bcl-2
family member protein MCL163, (iii) binding calcium (Ca2+) and
preventing Ca2+ from activating Ca2+-dependent apoptosis
pathway64, and (iv) binding and preventing IRE1α from activating the ER stress-induced apoptosis pathway5. Fortilin also
binds and potentiates the antioxidant activity of peroxiredoxin17. Further, fortilin is required for normal cell cycle progression
through the stabilization of microtubules6. Finally, we do not
know if fortilin in the extracellular space has functions other than
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binding to and blocking the signal transduction of TGF-β1. We
also do not know if TGF-β1 modulates the function of extracellular fortilin. Further investigation is needed to address these
questions.
TGF-β1 is involved in complex and diverse biological activities
in all organisms. TGF-β1 can suppress early-stage tumors
through its potent antiproliferative activity and the induction of
cell differentiation and apoptosis65,66. In advanced cancer, however, TGF-β1 actually promotes tumor invasion and metastasis by
inducing the epithelial-mesenchymal transition, facilitating tumor
angiogenesis, and hampering tumor immune surveillance by the
host65–67. TGF-β1 is also implicated in many ﬁbrotic human
diseases, including pulmonary ﬁbrosis68. Finally, TGF-β1 plays
critical roles in the negative regulation of the inﬂammatory
immune response69. The results of this study showing the physically and biologically meaningful interaction between fortilin
and TGF-β1 represent the beginning of our long-term investigation of the regulatory role of fortilin in numerous TGF-β1mediated biological processes and human diseases, including
cancer invasion, metastasis, immune surveillance, and angiogenesis; pulmonary ﬁbrosis and other ﬁbrotic diseases; and inﬂammatory diseases. Although its activities appear to be expansive
and complex, it is also possible that fortilin orchestrates seemingly diverse biological events to achieve a simple cellular goal
in response to certain microenvironmental changes.
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Images were electronically captured using the Bio-Rad ChemiDoc MP Imaging
System, and the signal intensities of protein bands were quantiﬁed using Image Lab
Software (Bio-Rad, Hercules, CA, USA). To quantify P-Smad3 expression in
relation to total proteins loaded, 0.5% (v/v) 2,2,2-trichloroethanol (TCE) was added
to a polyacrylamide gel before polymerization. After standard SDS-PAGE, the gel
was UV-irradiated on the Bio-Rad ChemiDoc MP Imaging System for 2 min, its
image was electronically captured, and the cumulative band densities were calculated to assess loading conditions as previously described71. The signal intensity of
western blot bands of P-Smad3 was then divided by that of the TCE bands to derive
the pSmad3 expression index, which was expressed as A.U. For the quantiﬁcation
of P-Smad3 expression in relation to total Smad3, the signal intensity of P-Smad3
bands quantiﬁed by Image Lab Software (Bio-Rad) was divided by that of corresponding total Smad3 bands, which was expressed as A.U.

Generation of recombinant human fortilin. Recombinant human fortilin (rhfortilin) was puriﬁed using the Strep-tag puriﬁcation system (IBA LifeSciences) as
described previously5 with slight modiﬁcation. Brieﬂy, 293T cells stably expressing
human fortilin with an N-terminal Strep-tag II tag (peptide sequence =
WSHPQFEK) were collected, washed in PBS, and resuspended in Buffer W
(100 mM Tris HCl, pH8, 150 mM NaCl, 1 mM EDTA, and protease inhibitor
cocktail, 1 tablet/mL). The cell suspension then was lysed by repeated freeze-thaw
cycles and sonicated to shear the genomic DNA. After centrifugation to remove the
cell pellet, the cleared cell lysate was passed through a gravity ﬂow Strep-Tactin®
XT Superﬂow® high-capacity column (IBA LIfeSciences). Next, the column was
washed ﬁve times with Buffer W and eluted with Buffer BXT (Buffer W containing
50 mM biotin). The Strep-tagged fortilin eluent fractions were pooled and concentrated using ultra centrifugal ﬁlter units (Amicon™, Millipore Sigma, Burlington,
MA, USA). The concentrated proteins were dialyzed in PBS using a Slide-A-Lyzer™
MINI dialysis device (Thermo Fisher Scientiﬁc, Waltham, MA, USA). Finally,
puriﬁed rh-fortilin was characterized by Stain-free total protein TCE® (Bio-Rad)
and western blot analyses.

Methods
Reagents and materials. Recombinant human TGF-β1, -β2, and -β3 (rh-TGF-β1,
-β2, β3) for Co-IP were obtained from eBioscience (San Diego, CA, USA; Catalog #:
14-8348-62), R&D Systems (Minneapolis, MN, USA; Catalog #: 302-B2-010/CF),
and R&D Systems (Catalog #: 243-B3-010/CF), respectively. Recombinant human
latency-associated-peptide (LAP)-TGF-β1 protein was purchased from R&D Systems (Catalog #: 246-LP-025/CF). Neutralizing anti-TGF-β antibody (Ab) was
obtained from R&D Systems (Catalog #: MAB1835-100, Clone: 1D11). Recombinant mouse TGF-β1 for luciferase, SEAP reporter, and Smad3 phosphorylation
assays on the MFB-F11 cells were purchased from R&D Systems (Catalog #: 7666MB/CF). Recombinant human TGF-β1 for C3H10T1/2 cell differentiation assays
was purchased from R&D Systems (Catalog #: 240-B-010). Human α-thrombin was
purchased from Haematologic Technologies (Catalog #: HT-0020, Essex Junction,
VT, USA). Agarose beads conjugated to anti-TGF-β1 monoclonal antibody (Clone:
3C11) were purchased from Santa Cruz Biotechnology (Dallas, TX, USA; Catalog #:
sc-130348 AC).
Cell culture. MycoFluor™ (Thermo Fisher Scientiﬁc-Molecular Probe, Eugene, OR,
USA) was used to detect mycoplasma contamination when appropriate. HEK293
(ATCC® CRL-1573™) cells were obtained from American Type Culture Collection
(ATCC, Manassas, VA, USA). Cells were maintained in Dulbecco’s modiﬁed
Eagle’s medium (DMEM) (Corning, Corning, NY, USA; Catalog #: 0-013-CV) with
10% fetal bovine serum (FBS) (Gibco Thermo Fisher, Waltham, MA, USA; Catalog
#: 10082-147) at 37 °C in an atmosphere containing 5% CO2. MFB-F11 cells21,22
were a kind gift from Dr. Tony Wyss-Coray (Stanford University, Stanford, CA,
USA). The cells were generated at the Wyss-Coray lab by stably transfecting mouse
embryonic ﬁbroblasts from Tgfb1−/− mice with a synthetic promoter element
containing twelve CAGA boxes fused to a SEAP reporter gene22. The cells were
initially propagated in DMEM supplemented with 10% FBS.
Western blot analyses. SDS-PAGE and western blot analyses were performed as
described previously2,14,15,64,70 on the lysates from the cell pellets. The following
primary antibodies were used at the indicated dilutions/concentrations: Antifortilin (Abcam, Waltham, MA, USA; Clone EPR5540, ab133568; 1:2000 dilution)
for Fig. S1c; anti-fortilin (MRB International, Woburn, MA, USA; Catalog #:
PM017; 1:1000 dilution) for Fig. S3; anti-Gaussia luciferase (GLuc, NEB, Ipswich,
MA, USA; Catalog #: E8023; 1:500 dilution); anti-TGF-β1 (Abcam; Clone
EPR18163, ab179695; 1:1000 dilution) for Western blot analysis of Fig. 1a and
Fig. S1c; anti-TGF-β1/2/3 (denoted anti-TGF-β) (R&D Systems, Minneapolis, MN,
USA; Clone 1D11, MAB1835-100; 1:1000 dilution) for western blot analysis of
Fig. 1b; anti-Flag (Sigma, St. Louis, MO, USA; Clone M2, F1804; 1:1000 dilution);
anti-His6 (Abcam; Clone HIS.H8, ab18184; 1:1000 dilution); anti-GAPDH (Santa
Cruz Biotechnology, Dallas, TX, USA; Clone 6C5, sc-32233; 1:10,000 dilution);
anti-Strep-tag (IBA Lifesciences, Göttingen, Germany; 2-1507-001; 1:1000 dilution); anti-P-Smad3 (Rockland Immunochemicals, Limerick, PA, USA; Clone
AF9F7, 600-401-919; 1:1000 dilution); anti-Smad3 (Abcam; Clone HIS.H8,
ab75512; 1:1000 dilution). All antibodies were used with appropriate IRDye680LTor IRDye800CW-conjugated secondary antibodies (LI-COR, Lincoln, NE, USA).

Co-IP-western blot analysis. Co-IP of TGF-β1 by fortilin: To evaluate whether
fortilin speciﬁcally interacts with TGF-β1, we added recombinant human (rh) ﬂagtagged fortilin (OriGene, Rockville, MD, USA; Catalog #: TP301664), rh-ﬂagtagged p53 (OriGene, Catalog #: TP300003), rh-His6-tagged NQO2 (Abcam,
Catalog #: ab93933), and rh-TGF-β1 (eBioscience, Catalog #: 14-8348-62) to
Bufffer A (10 mM Tris, pH 7.4, 100 mM NaCl, 0.01% NP-40, 2 mM phenylmethylsulfonyl ﬂuoride (PMSF), protease inhibitor cocktail, 1 tablet/mL), mixed
the solution by pipetting, took 10% of the total volume for the analysis of input,
and added a 100 µL aliquot to Tube A and to Tube B. We added 3 µg each of rabbit
IgG isotype control (Thermo Fisher Scientiﬁc, Catalog #: AB-105-C) and rabbit
anti-fortilin antibody (Abcam, Catalog #: ab133568, Clone: EPR5540) to Tubes A
and B, respectively, and incubated them at room temperature for 2 h. We then
added 50 µL of pre-washed Dynabeads™ M-280 (Thermo Fisher Scientiﬁc) coated
with sheep anti-rabbit IgG to these tubes to immunoprecipitate the immune
complexes that had formed. We washed the beads four times using Buffer B
(10 mM Tris, pH 7.4, 100 mM NaCl, 0.3% NP-40, 2 mM PMSF, protease inhibitor
cocktail, 1 tablet/mL) and eluted the immune complexes into SDS-loading buffer.
Western transfer and immunoblotting were performed as described previously and
using anti-Flag (Sigma, Catalog #: F1804, Clone: M2), anti-TGF-β1 (Abcam,
Catalog #: ab179695, Clone: EPR18163), anti-TGF-β1/β2/β3 (R&D Systems, Catalog #: MAB1835-100, Clone: 1D11), and anti-His6 (Abcam, Catalog #: ab18184,
Clone: HIS:H8) antibodies. Co-IP of TGF-β2 and -β3 by fortilin: For the Co-IP of
TGF-β2 and -β3 by fortilin, the same procedure was repeated using rh-TGF-β2
(R&D Systems, Catalog #: 302-B2-010/CF), rh-TGF-β3 (R&D Systems, Catalog #:
243-B3-010/CF), and Buffer B for the wash, which was performed ﬁve times
instead of four times.

Generation of TGF-β1-rich sera. De-identiﬁed human platelet units were obtained
from the University of Washington Blood Bank (Seattle, WA, USA) and stored at
–80 °C until used in the experiment. After the unit was thawed, we added thrombin
at the ﬁnal concentration of 0.5 unit/mL, immediately mixed the solution, incubated it at room temperature for 10 min with gentle shaking, centrifuged the
mixture at 10,000 × g. We collected the separated supernatant, labeled it “sera”, and
stored it at −80 °C.
Immunodepletion of fortilin or TGF-β1 from human sera. Mouse anti-TGF-β
monoclonal antibody (α-TGF-β mAb, Catalog #: MAB1835-100, Clone 1D11, R&D
Systems) and α-fortilin mAb were coupled to Dynabeads® M-280 tosylactivated
magnetic beads (Thermo Fisher Scientiﬁc) according to the manufacturer’s
instructions. We incubated 180 µL of the platelet-rich sera with 100 µL each of
magnetic beads (20 mg/mL) coupled with either α-TGF-β or α-fortilin mAbs for
2 h at 37 °C, immobilized the beads with a magnet, and transferred the supernatants (the sera immunodepleted of fortilin and TGF-β) to fresh microfuge tubes.
We repeated the process twice before we stored the samples at –80 °C until the
ELISA experiments.
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ELISA. TGF-β1 ELISA: For ELISA of TGF-β1, the TGF-β1 human ELISA kit was
purchased from Abcam (Catalog #: ab100647) and used according to the manufacturer’s instructions. We ﬁrst applied 100 µL of control and study sera to the wells
of a 96-well strip plate that had already been pre-coated with α-TGF-β1 capturing
antibody. After incubating the plate for 2.5 h at room temperature with gentle
shaking and washing it extensively with wash buffer provided by the manufacturer,
we added 100 µL of biotinylated α-TGF-β1 detection antibody and incubated it for
1 h at room temperature. After another extensive wash, we added horse-radishperoxidase (HRP)-conjugated streptavidin solution to each well and incubated it
for 45 min at room temperature with gentle shaking. After a ﬁnal extensive wash,
we added 3,3′,5,5′-tetramethylbenzidine (TMB) substrate solution to each well,
incubated the plate in the dark for 30 min at room temperature with gentle shaking,
added 50 µL of stop solution to each well, and obtained the absorbance at 450 nm
(Abs450), using the Multilabel Plate Reader (Victor 3 V, Model 1420, Perkin Elmer,
Waltham, MA, USA). Fortilin ELISA: For ELISA of fortilin, we ﬁrst biotinylated αfortilin mAb using the Lighting-Link® Biotinylation Kit (Catalog #: ab201795,
Abcam). We then coated the wells of a 96-well plate (Clear Flat Bottom Polystyrene
High Bind Microplate, Corning; Catalog #: 9018) by adding 200 µL of 1 µg/mL αfortilin mAb to the wells. We incubated the plate for 1 h at 37 °C and then washed
it three times with wash buffer (PBS with 150 mM NaCl, 0.05% Tween 20). We
then applied 100 µL of control and study sera to the wells of the plate. After
incubating the plate for 2.5 h at room temperature with gentle shaking and washing
it extensively, we added 100 µL of biotinylated α-fortilin detection antibody and
incubated it for 1 h at room temperature. After extensive washing, we added HRPstreptavidin solution (Abcam, Catalog #: ab7403) to each well and incubated the
plate for 45 min at room temperature with gentle shaking. Finally, after extensive
washing, we added TMB substrate solution (Abcam, Catalog #: ab171522) to each
well, incubated the plate in the dark for 3 min at room temperature with gentle
shaking, added 100 µL of stop solution (Abcam, Catalog #: ab171529) to each well,
and obtained the absorbance at 450 nm. Modiﬁed ELISA to detect the fortilin-TGFβ1 interaction in vivo: To evaluate the in vivo complexing between TGF-β1 and
fortilin, we ﬁrst applied 100 µL of these samples to the wells of a 96-well TGF-β1
human ELISA strip plate (Abcam, Catalog #; 100647) that had already been precoated with α-TGF-β1 capturing antibody. After incubating the plate for 2.5 h at
room temperature with gentle shaking and washing it extensively, we added 100 µL
of biotinylated α-fortilin detection antibody and incubated it for 1 h at room
temperature. After extensive washing, we added HRP-streptavidin solution to each
well and incubated the plate for 45 min at room temperature with gentle shaking.
Finally, after extensive washing, we added TMB substrate solution (Abcam) to each
well, incubated it in the dark for 30 min at room temperature with gentle shaking,
added 50 µL of stop solution (Abcam) to each well, and obtained the absorbance at
450 nm.
MILLIPLEX® multiplex immunoassays to detect mouse serum TGF-β1, TGFβ2, and TGF-β3. We determined the serum concentrations of TGF-β1, TGF-β2,
and TGF-β3 by diluting mouse serum samples by adding 1 part of serum to 29
parts of Sample Diluent (Catalog #: LTGF-SD, Millipore Sigma, Burlington, MA,
USA) and subjecting them to MILLIPLEX® multiplex immunoassays (Catalog #:
TGFBMAG-64K-03, Millipore Sigma), according to the manufacturer’s
instructions.
Co-puriﬁcation of fortilin by column-based afﬁnity puriﬁcation of TGF-β1. We
performed all steps in 4 °C. To test if afﬁnity-puriﬁed TGF-β1 is bound to fortilin,
we ﬁrst packed a gravity chromatography column (Bio-Rad Poly-Prep Chromatography Columns) with 1 mL agarose beads conjugated to anti-TGF-β1 antibody
(Santa Cruz Biotechnology) and equilibrated it with 10-column volume (CV) of
Wash Buffer (phosphate-buffered saline (PBS)) (Figs. S1b-1). Next, we loaded the
column with 10 mL of platelet-rich sera diluted 10-fold in Wash Buffer (Figs. S1b2) and collected the entire ﬂow through (FT). Next, we washed the column with 10
CV of Wash Buffers 5 times (Figs. S1b-3). We collected ﬂow throughs (WASH-1,
-2, -3, -4, and -5) and monitored their protein concentrations using NanoDrop™
One (ThermoFisher Scientiﬁc). Preliminary experiments had showed that protein
concentrations of WASH-4 and WASH-5 were barely detectable using NanoDrop
One (Thermo Scientiﬁc). We then put the bottom cap onto the column, added
1 mL of Elution Buffer (0.1 M Glycine-HCl, pH = 3.0), incubated for 1 min, and
collected the eluate (EL-1). We repeated the step two more times to collect EL-2
and EL-3 (Figs. S1b-4). We pooled together EL-1, EL-2, and EL-3 and concentrated
it to 73 µL (ELUATE), using a protein concentrator spin column (Amicon Ultra0.5 centrifugal ﬁlter unit, Millipore Sigma, Burlington, MA, USA; Catalog #:
UFC5010). Finally, we subjected 37.5 µL each of platelet-rich sera (INPUT), FT,
WASH-1, WASH-2, WASH-4, WASH-5, and ELUATE to western blot analysis
using anti-fortilin (Abcam, EPR5540) and anti-TGF-β1 (Abcam EPR18163).
BLI analysis. The interaction between fortilin and TGF-β1 was evaluated using the
BLItz System (ForteBio) as described previously5. First, rh-fortilin protein was
biotinylated by mixing it with 2 mM NHS-PEG4-biotin solution and incubating the
mixture for 30 min at room temperature. The biotinylated protein was then puriﬁed to remove free biotin using Zeba™ Spin Desalting Columns (Thermo Fisher
Scientiﬁc). Next, the biotinylated fortilin was immobilized on streptavidin-coated
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biosensors (ForteBio) at a concentration of 30 μg/mL in PBS for 600 s. After
fortilin-coated biosensors were buffer-exchanged in PBS for 30 s, various concentrations of rh-TGF-β1 (OriGene; Catalog #: TP300973) were added for 180 s to
evaluate the association between the two proteins. Finally, rh-TGF-β1 protein
solution was replaced by PBS for 180 s to evaluate their dissociation. The binding
data were processed, and a dissociation constant (Kd) was calculated using BLItz
analysis software based on two independent experiments. The same procedure was
performed for the LAP-TGF-β1 protein (R&D Systems), except the Kd was calculated based on three independent experiments.
SPR analysis. All experiments were performed using a Biacore 3000 (Uppsala,
Sweden) and carried out at 25 °C using HBS-EPS (0.01 M HEPES, 0.5 M NaCl,
3 mM EDTA, 0.005% (v/v) Tween 20, pH 7.4) as running buffer. The experimental
ﬂow rate was 20 μL/min. Different forms of rh-fortilin were immobilized onto three
ﬂow channels (FCs) of a CM5 chip using amine-coupling chemistry as follows:
FC2: 7060 RU N-His6-fortilin; FC3: 3223 RU C-His6-fortilin; FC4: 3667 RU streptag-fortilin. To scout for binding conditions, rh-TGF-β1 produced in-house was
injected at a concentration of 100 nM over each channel. To obtain binding rates,
rh-TGF-β1 was injected over N-His6-fortilin at the indicated concentrations.
Binding rates were calculated by ﬁtting data to a 1:1 Langmuir interaction model
with mass transport limitation using BiaEvaluation software (Biacore). Kds were
determined by calculating the ratio of binding and dissociation rate constants. For
inhibition analysis, 100 nM rh-TGF-β1 was pre-incubated with indicated concentrations of the inhibitor rh-TGFβRII-Fc and injected over experimental and
control ﬂow channels19. After each binding cycle, the fortilin-coupled surface was
regenerated to base line by injecting 20 µL of 1 M NaCl.
Luciferase assay using HEK293SBE-Luc cells. We transiently transfected HEK293
cells with the SBE-luciferase vector (pGL4.48 [luc2P/SBE/Hygro], Promega,
Madison, WI, USA) along with the Renilla luciferase control reporter vector (pRL,
Promega), which allowed us to normalize ﬁreﬂy luciferase activities according to
transfection efﬁciency. The following day, we treated the transfected HEK293 cells
with rh-TGF-β1 (1 nM) or vehicle (PBS) in the presence and absence of step-tagfortilin (3 nM) in quadruplicate, incubated the samples for 18 h at 37 °C, and
subjected the cells to the Dual-Glo-Luciferase Assay System (Promega) according
to the manufacturer’s instructions. We calculated relative luciferase activity (FLU/
RLU) by dividing ﬁreﬂy luciferase units (FLU) by Renilla luciferase units (RLU)
and expressed the results as A.U. We then normalized FLU/RLU of the cells treated
with rh-TGF-β1 to that of the cells treated with vehicle in either the presence or
absence of fortilin.
SEAP reporter assay using MFB-F11SBE-SEAP cells. MFB-F11 cells21,22 were a
kind gift from Dr. Tony Wyss-Coray (Stanford University, Stanford, CA, USA).
The cells were generated at the Wyss-Coray lab by stably transfecting mouse
embryonic ﬁbroblasts from Tgfb1−/− mice with a synthetic promoter element
containing 12 CAGA boxes fused to a SEAP reporter gene22. The cells were kept
and propagated in DMEM supplemented with 10% FBS. For SEAP reporter assays,
we ﬁrst acclimated murine MFB-F11 cells in FibroLife Fibroblast Serum Free
Medium (LifeLine Cell Technology, Oceanside, CA, USA) with 1% FBS. We seeded
MFB-F11 cells in a 96-well plate at 50,000 cells per well (N = 6 each) and incubated
them for 24 h. The next morning, we replaced the medium with 100 µL of FibroLife
without FBS and incubated the cells at 37 °C for 2 h. We then stimulated the cells
with recombinant mouse (rm) TGF-β1 (R&D Systems, Catalog #: 7666-MB/CF;
156 pM or 2000 pg/mL) pre-incubated with strep-tagged rh-fortilin (either 19.5 or
195 nM), strep-tagged recombinant luciferase (either 19.5 or 195 nM), or antiTGF-β1 monoclonal antibody (R&D Systems, Catalog #: MAB1835-100, Clone:
1D11) for 24 h at 37 °C. We then subjected 40 µL of supernatants to the PhosphaLight™ SEAP Reporter Gene assay (Thermo Fisher Scientiﬁc, Catalog #: T1015)
according to the manufacturer’s instructions.
Smad3 phosphorylation assay by western blot analysis and ELISA. We seeded
0.7 × 106 FibroLife-acclimated MFB-F11SBE-SEAP cells in each well of 6-well plates
and incubated them for 24 h. We then replaced the medium with 100 µL of
FibroLife without FBS and incubated the cells at 37 °C for 2 h. Next, we stimulated
the cells for 45 min at 37 °C with rm-TGF-β1 (2 ng/mL or 156 pM) that had been
pre-incubated with either fortilin or control luciferase proteins. We harvested the
cells for either standard western blot analysis or the P-Smad3 (pS423/S425) ELISA,
with the latter following the manufacturer’s instructions (Abcam, Catalog #:
ab186038).
Quantitative real-time PCR. Mouse embryonic ﬁbroblast C3H10T1/2 cells were
seeded in a 12-well plate at a density of 1 × 105 cells/well and cultured overnight.
Cells were starved with DMEM containing 0.1% FBS for 48 h, followed by incubation with fortilin (0.5 µg/mL), TGF-β1 (1 ng/mL), or their mixture for 8 h. All
proteins, individually or in mixture, were incubated in the starving medium at
room temperature for 30 min before treatment. Total RNA was isolated at 8 h after
treatment using TRIzol (Invitrogen, Carlsbad, CA, USA). cDNA was synthesized
using the iScript™ cDNA Synthesis Kit (Bio-Rad). PCR was performed using the
All-in-One™ qPCR mix (GeneCopoeia, Rockville, MD, USA) on an AriaMx Real-
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time PCR system (Agilent, Santa Clara, CA, USA) following the manufacturer’s
instructions. Cyclophilinm (CYP) was used as an internal reference. The primers
(Integrated DNA Technologies, Coralville, IA, USA) were as follows: CNN1, Forward: 5′-GGATGTGACAGCAGCGTTTG-3′, Reverse: 5′-GGCCCCAAGACTCC
AATGAT-3′; α-SMA, Forward: 5′-AATGGCTCTGGGCTCTGTAAG-3′, Reverse:
5′-CACGATGGATGGGAAAACAGC-3′; SM22α, Forward: 5′-GGTCCATCCTAC
GGCATGAG-3′, Reverse: 5′-CCTACATCAGGGCCACACTG-3′; CYP, Forward:
5′-CAGACGCCACTGTCGCTTT-3′, Reverse: 5′-TGTCTTTGGAACTTTGTCTG3′. Gene expression was calculated using the 2–ΔΔCt method. The experiments were
independently repeated three times.
Analysis and alignments of TGF-β isoform sequences. TGF-β1, -β2, and
-β3 sequences were obtained from Mittl et al.72. Unipro UGENE v34.0 (Unipro,
Novosibirsk, Russia) was used to align their sequences and visualize the alignment
according to the developers’ instructions73.

4.
5.
6.
7.

8.
9.

10.

Computational molecular docking of fortilin, TGF-β1, and TGFβRII. Threedimensional protein structural models of fortilin (PDB ID: 2HR9), TGF-β1 (PDB
ID: 3KFD), and the TGF-β1:TGFβRII complex (PDB ID: 5TY4) for docking
experiments were obtained from the Research Collaboratory for Structural Bioinformatics (RCSB) Protein Data Bank (PDB)29,74–76. Protein–protein docking of
fortilin with TGF-β1 and TGF-β1:TGFβRII was performed using the ClusPro
server utilizing the PIPER docking algorithm33,34,77,78. For the docking procedures,
the center-of-mass (COM) of the receptor TGF-β1 protein (or TGF-β1:TGFβRII)
was ﬁxed, and the fortilin position was sampled at 70,000 possible rotational
orientations about the COM. At each rotational position, the ligand translational
position was sampled at a resolution of 1 Å to ﬁnd the corresponding lowest-energy
conformation. In total, the algorithm sampled ~109 possible relative orientations of
the proteins. Interaction energies (or scores) for each conformation were calculated
using an electrostatic-favored weighting due to the overall high density of charged
residues on the protein surfaces. The docking procedure is followed by clustering of
similarly oriented structures of the 1000 lowest-energy structures. The interfacial
root mean squared deviation (IRMSD) of backbone atoms are calculated for each
structure, and that with the largest number of neighboring structures within a 9 Å
radius is deﬁned as the center of the ﬁrst cluster. All protein–protein orientations
within the 9 Å IRMSD are considered part of the ﬁrst cluster and removed from the
population. The procedure is repeated for the remaining population until all
docked structures are clustered. The populations of the resulting clusters are
proportional to the thermodynamic probabilities of ﬁnding the proteins in each
speciﬁc binding orientation. The scores are calculated from molecular mechanics
(CHARMM force ﬁeld) for the structures obtained from docking.

11.

Statistics and reproducibility. The degree of the spread of data was expressed by
the standard deviation (mean ± SD). Student’s t-test was used to compare the
means of two groups. To compare the means of three groups, we used one-way
ANOVA with Fisher’s pairwise comparison. P < 0.05 was considered to be statistically signiﬁcant. P < 0.10 was considered to show a trend toward statistical signiﬁcance. The numbers of biological replicates used in in vivo experiments were
determined by (i) power analysis, assuming an α error rate of 0.05, β error rate of
0.20, and expected difference of 25% and using Minitab 17 (State College, PA,
USA) or (ii) our previous dataset and experience from similar experiments performed in the past.

20.

12.

13.
14.

15.

16.

17.

18.
19.

21.

22.

23.

Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.

24.

Data availability

25.

The authors declare that the data supporting the ﬁndings of this study are available
within the paper and its supplementary information ﬁles (Figs. S1–S10 and
Supplementary Data 1). All relevant data are available from the authors upon request.

Received: 16 October 2021; Accepted: 28 January 2022;

26.

27.

28.

References
1.

2.
3.

Gross, B., Gaestel, M., Bohm, H. & Bielka, H. cDNA sequence coding for a
translationally controlled human tumor protein. Nucleic Acids Res. 17, 8367
(1989).
Li, F., Zhang, D. & Fujise, K. Characterization of fortilin, a novel antiapoptotic protein. J. Biol. Chem. 276, 47542–47549 (2001).
Tuynder, M. et al. Biological models and genes of tumor reversion: cellular
reprogramming through tpt1/TCTP and SIAH-1. Proc. Natl Acad. Sci. USA
99, 14976–14981 (2002).

29.

30.
31.

Yang, Y. et al. An N-terminal region of translationally controlled tumor protein
is required for its antiapoptotic activity. Oncogene 24, 4778–4788 (2005).
Pinkaew, D. et al. Fortilin binds IRE1α and prevents ER stress from signaling
apoptotic cell death. Nat. Commun. 8, 1–16 (2017).
Yarm, F. R. Plk phosphorylation regulates the microtubule-stabilizing protein
TCTP. Mol. Cell Biol. 22, 6209–6221 (2002).
Chattopadhyay, A. et al. Fortilin potentiates the peroxidase activity of
Peroxiredoxin-1 and protects against alcohol-induced liver damage in mice.
Sci. Rep. 6, 18701 (2016).
Kashiwakura, J. I. et al. Histamine-releasing factor has a proinﬂammatory role
in mouse models of asthma and allergy. J. Clin. Invest. 122, 218–228 (2011).
MacDonald, S. M., Rafnar, T., Langdon, J. & Lichtenstein, L. M. Molecular
identiﬁcation of an IgE-dependent histamine-releasing factor. Science 269,
688–690 (1995).
Sinthujaroen, P. et al. Elevation of serum fortilin levels is speciﬁc for apoptosis
and signiﬁes cell death in vivo. BBA Clin. 2, 103–111 (2014).
Amzallag, N. et al. TSAP6 facilitates the secretion of translationally controlled
tumor protein/histamine-releasing factor via a nonclassical pathway. J. Biol.
Chem. 279, 46104–46112 (2004).
Chen, Y. et al. Physical and functional antagonism between tumor suppressor
protein p53 and fortilin, an anti-apoptotic protein. J. Biol. Chem. 286,
32575–32585 (2011).
Amson, R. et al. Reciprocal repression between P53 and TCTP. Nat. Med. 18,
91–99 (2011).
Graidist, P., Phongdara, A. & Fujise, K. Antiapoptotic protein partners fortilin
and MCL1 independently protect cells from 5-FU-induced cytotoxicity. J. Biol.
Chem. 279, 40868–40875 (2004).
Zhang, D., Li, F., Weidner, D., Mnjoyan, Z. H. & Fujise, K. Physical and
functional interaction between MCL1 and fortilin. The potential role of MCL1
as a fortilin chaperone. J. Biol. Chem. 277, 37430–37438 (2002).
Wakeﬁeld, L. M. et al. Transforming growth factor-beta1 circulates in normal
human plasma and is unchanged in advanced metastatic breast cancer. Clin.
Cancer Res. 1, 129–136 (1995).
Mancini, D. et al. New methodologies to accurately assess circulating active
transforming growth factor-beta1 levels: implications for evaluating heart
failure and the impact of left ventricular assist devices. Transl. Res. 192, 15–29
(2018).
Derynck, R. & Budi, E. H. Speciﬁcity, versatility, and control of TGF-beta
family signaling. Sci. Sig. 12, eaav5183 (2019).
Aykul, S. & Martinez-Hackert, E. Determination of half-maximal inhibitory
concentration using biosensor-based protein interaction analysis. Anal.
Biochem 508, 97–103 (2016).
Dennler, S. et al. Direct binding of Smad3 and Smad4 to critical TGF betainducible elements in the promoter of human plasminogen activator
inhibitor-type 1 gene. EMBO J. 17, 3091–3100 (1998).
Tesseur, I., Zou, K., Berber, E., Zhang, H. & Wyss-Coray, T. Highly sensitive
and speciﬁc bioassay for measuring bioactive TGF-beta. BMC Cell Biol. 7, 15
(2006).
Broekelmann, T. J., Bodmer, N. K. & Mecham, R. P. Identiﬁcation of the
growth factor-binding sequence in the extracellular matrix protein MAGP-1.
J. Biol. Chem. 295, 2687–2697 (2020).
Basatemur, G. L., Jorgensen, H. F., Clarke, M. C. H., Bennett, M. R. & Mallat,
Z. Vascular smooth muscle cells in atherosclerosis. Nat. Rev. Cardiol. 16,
727–744 (2019).
Liu, R. & Jin, J. P. Calponin isoforms CNN1, CNN2 and CNN3: regulators for
actin cytoskeleton functions in smooth muscle and non-muscle cells. Gene
585, 143–153 (2016).
Chen, S. & Lechleider, R. J. Transforming growth factor-beta-induced
differentiation of smooth muscle from a neural crest stem cell line. Circ. Res.
94, 1195–1202 (2004).
Reznikoff, C. A., Brankow, D. W. & Heidelberger, C. Establishment and
characterization of a cloned line of C3H mouse embryo cells sensitive to
postconﬂuence inhibition of division. Cancer Res. 33, 3231–3238 (1973).
Hirschi, K. K., Rohovsky, S. A. & D’Amore, P. A. PDGF, TGF-beta, and
heterotypic cell-cell interactions mediate endothelial cell-induced recruitment
of 10T1/2 cells and their differentiation to a smooth muscle fate. J. Cell Biol.
141, 805–814 (1998).
Huang, H. Y. et al. Induction of EMT-like response by BMP4 via upregulation of lysyl oxidase is required for adipocyte lineage commitment. Stem
Cell Res. 10, 278–287 (2013).
Radaev, S. et al. Ternary complex of transforming growth factor-beta1 reveals
isoform-speciﬁc ligand recognition and receptor recruitment in the
superfamily. J. Biol. Chem. 285, 14806–14814 (2010).
Hart, P. J. et al. Crystal structure of the human TbetaR2 ectodomain–TGFbeta3 complex. Nat. Struct. Biol. 9, 203–208 (2002).
Comeau, S. R., Gatchell, D. W., Vajda, S. & Camacho, C. J. ClusPro: a fully
automated algorithm for protein-protein docking. Nucleic Acids Res. 32,
W96–W99 (2004).

COMMUNICATIONS BIOLOGY | (2022)5:157 | https://doi.org/10.1038/s42003-022-03112-6 | www.nature.com/commsbio

11

ARTICLE

COMMUNICATIONS BIOLOGY | https://doi.org/10.1038/s42003-022-03112-6

32. Comeau, S. R., Gatchell, D. W., Vajda, S. & Camacho, C. J. ClusPro: an
automated docking and discrimination method for the prediction of protein
complexes. Bioinformatics 20, 45–50 (2004).
33. Kozakov, D. et al. The ClusPro web server for protein-protein docking. Nat.
Protoc. 12, 255–278 (2017).
34. Vajda, S. et al. New additions to the ClusPro server motivated by CAPRI.
Proteins 85, 435–444 (2017).
35. Aykul, S. & Martinez-Hackert, E. Transforming growth factor-beta family
ligands can function as antagonists by competing for type II receptor binding.
J. Biol. Chem. 291, 10792–10804 (2016).
36. Massague, J. TGF-beta signal transduction. Annu. Rev. Biochem. 67, 753–791
(1998).
37. Souchelnytskyi, S., ten Dijke, P., Miyazono, K. & Heldin, C. H.
Phosphorylation of Ser165 in TGF-beta type I receptor modulates TGF-beta1induced cellular responses. EMBO J. 15, 6231–6240 (1996).
38. Wrana, J. L., Attisano, L., Wieser, R., Ventura, F. & Massague, J. Mechanism of
activation of the TGF-beta receptor. Nature 370, 341–347 (1994).
39. Wieser, R., Wrana, J. L. & Massague, J. GS domain mutations that
constitutively activate T beta R-I, the downstream signaling component in the
TGF-beta receptor complex. EMBO J. 14, 2199–2208 (1995).
40. Murphy-Ullrich, J. E., Schultz-Cherry, S. & Hook, M. Transforming growth
factor-beta complexes with thrombospondin. Mol. Biol. Cell 3, 181–188
(1992).
41. Young, G. D. & Murphy-Ullrich, J. E. The tryptophan-rich motifs of the
thrombospondin type 1 repeats bind VLAL motifs in the latent transforming
growth factor-beta complex. J. Biol. Chem. 279, 47633–47642 (2004).
42. Crawford, S. E. et al. Thrombospondin-1 is a major activator of TGF-beta1
in vivo. Cell 93, 1159–1170 (1998).
43. Philip, A., Bostedt, L., Stigbrand, T. & O’Connor-McCourt, M. D. Binding of
transforming growth factor-beta (TGF-beta) to pregnancy zone protein (PZP).
Comparison to the TGF-beta-alpha 2-macroglobulin interaction. Eur. J.
Biochem. 221, 687–693 (1994).
44. Robertson, I. B. & Rifkin, D. B. Regulation of the bioavailability of TGF-beta
and TGF-beta-related proteins. Cold Spring Harb. Perspect. Biol. 8, a021907
(2016).
45. Kizawa, H. et al. An aspartic acid repeat polymorphism in asporin inhibits
chondrogenesis and increases susceptibility to osteoarthritis. Nat. Genet. 37,
138–144 (2005).
46. Yamaguchi, Y., Mann, D. M. & Ruoslahti, E. Negative regulation of
transforming growth factor-beta by the proteoglycan decorin. Nature 346,
281–284 (1990).
47. Schachtrup, C. et al. Fibrinogen triggers astrocyte scar formation by
promoting the availability of active TGF-beta after vascular damage. J.
Neurosci. 30, 5843–5854 (2010).
48. Martino, M. M., Briquez, P. S., Ranga, A., Lutolf, M. P. & Hubbell, J. A.
Heparin-binding domain of ﬁbrin(ogen) binds growth factors and promotes
tissue repair when incorporated within a synthetic matrix. Proc. Natl Acad.
Sci. USA 110, 4563–4568 (2013).
49. Hildebrand, A. et al. Interaction of the small interstitial proteoglycans
biglycan, decorin and ﬁbromodulin with transforming growth factor beta.
Biochem. J. 302, 527–534 (1994).
50. Oganesian, A. et al. The NH2-terminal propeptide of type I procollagen acts
intracellularly to modulate cell function. J. Biol. Chem. 281, 38507–38518
(2006).
51. Zhu, Y., Oganesian, A., Keene, D. R., Sandell, L. J. & Type, I. I. A. procollagen
containing the cysteine-rich amino propeptide is deposited in the extracellular
matrix of prechondrogenic tissue and binds to TGF-beta1 and BMP-2. J. Cell
Biol. 144, 1069–1080 (1999).
52. Cheifetz, S. et al. Endoglin is a component of the transforming growth factorbeta receptor system in human endothelial cells. J. Biol. Chem. 267,
19027–19030 (1992).
53. Lebrin, F. et al. Endoglin promotes endothelial cell proliferation and TGFbeta/ALK1 signal transduction. EMBO J. 23, 4018–4028 (2004).
54. Chen, K., Mehta, J. L., Li, D., Joseph, L. & Joseph, J. Transforming growth
factor beta receptor endoglin is expressed in cardiac ﬁbroblasts and modulates
proﬁbrogenic actions of angiotensin II. Circ. Res. 95, 1167–1173 (2004).
55. Lee, N. Y., Ray, B., How, T. & Blobe, G. C. Endoglin promotes transforming
growth factor beta-mediated Smad 1/5/8 signaling and inhibits endothelial cell
migration through its association with GIPC. J. Biol. Chem. 283, 32527–32533
(2008).
56. Zhang, L. et al. Modulation of TGF-beta signaling by endoglin in murine
hemangioblast development and primitive hematopoiesis. Blood 118, 88–97
(2011).
57. Lux, A., Attisano, L. & Marchuk, D. A. Assignment of transforming growth
factor beta1 and beta3 and a third new ligand to the type I receptor ALK-1. J.
Biol. Chem. 274, 9984–9992 (1999).
58. Albinana, V., Sanz-Rodriguez, F., Recio-Poveda, L., Bernabeu, C. & Botella, L.
M. Immunosuppressor FK506 increases endoglin and activin receptor-like

12

59.

60.
61.

62.

63.

64.
65.
66.
67.

68.

69.

70.
71.

72.
73.
74.
75.

76.
77.
78.

kinase 1 expression and modulates transforming growth factor-beta1 signaling
in endothelial cells. Mol. Pharm. 79, 833–843 (2011).
Tanaka, M. et al. DIP2 disco-interacting protein 2 homolog A (Drosophila) is a
candidate receptor for follistatin-related protein/follistatin-like 1–analysis of their
binding with TGF-beta superfamily proteins. FEBS J. 277, 4278–4289 (2010).
Dong, Y. et al. Blocking follistatin-like 1 attenuates bleomycin-induced
pulmonary ﬁbrosis in mice. J. Exp. Med. 212, 235–252 (2015).
Danielpour, D. & Sporn, M. B. Differential inhibition of transforming growth
factor beta 1 and beta 2 activity by alpha 2-macroglobulin. J. Biol. Chem. 265,
6973–6977 (1990).
Mousseau, D. D. et al. A direct interaction between transforming growth
factor (TGF)-betas and amyloid-beta protein affects ﬁbrillogenesis in a TGFbeta receptor-independent manner. J. Biol. Chem. 278, 38715–38722 (2003).
Liu, H., Peng, H. W., Cheng, Y. S., Yuan, H. S. & Yang-Yen, H. F. Stabilization
and enhancement of the antiapoptotic activity of mcl-1 by TCTP. Mol. Cell
Biol. 25, 3117–3126 (2005).
Graidist, P. et al. Fortilin binds Ca2+ and blocks Ca2+-dependent apoptosis
in vivo. Biochem. J. 408, 181–191 (2007).
Derynck, R., Akhurst, R. J. & Balmain, A. TGF-beta signaling in tumor
suppression and cancer progression. Nat. Genet. 29, 117–129 (2001).
Seoane, J. & Gomis, R. R. TGF-beta family signaling in tumor suppression and
cancer progression. Cold Spring Harb. Perspect. Biol. 9, a022277 (2017).
Yang, Y. et al. The role of TGF-beta signaling pathways in cancer and its
potential as a therapeutic target. Evid. Based Complement Alternat. Med. 2021,
6675208 (2021).
Budi, E. H., Schaub, J. R., Decaris, M., Turner, S. & Derynck, R. TGF-beta as a
driver of ﬁbrosis: physiological roles and therapeutic opportunities. J. Pathol.
254, 358–373 (2021).
Li, M. O., Wan, Y. Y., Sanjabi, S., Robertson, A. K. & Flavell, R. A.
Transforming growth factor-beta regulation of immune responses. Annu. Rev.
Immunol. 24, 99–146 (2006).
Fujita, T. et al. Human fortilin is a molecular target of dihydroartemisinin.
FEBS Lett. 582, 1055–1060 (2008).
Ladner, C. L., Edwards, R. A., Schriemer, D. C. & Turner, R. J. Identiﬁcation of
trichloroethanol visualized proteins from two-dimensional polyacrylamide
gels by mass spectrometry. Anal. Chem. 78, 2388–2396 (2006).
Mittl, P. R. et al. The crystal structure of TGF-beta 3 and comparison to TGFbeta 2: implications for receptor binding. Protein Sci. 5, 1261–1271 (1996).
Okonechnikov, K., Golosova, O., Fursov, M. & team, U. Unipro UGENE: a
uniﬁed bioinformatics toolkit. Bioinformatics 28, 1166–1167 (2012).
Berman, H. M. et al. The Protein Data Bank. Nucleic Acids Res. 28, 235–242
(2000).
Feng, Y., Liu, D., Yao, H. & Wang, J. Solution structure and mapping of a very
weak calcium-binding site of human translationally controlled tumor protein
by NMR. Arch. Biochem. Biophys. 467, 48–57 (2007).
de la Cruz, M. J. et al. Atomic-resolution structures from fragmented protein
crystals with the cryoEM method MicroED. Nat. Methods 14, 399–402 (2017).
Desta, I. T., Porter, K. A., Xia, B., Kozakov, D. & Vajda, S. Performance and its
limits in rigid body protein-protein docking. Structure 28, 1071–81 e3 (2020).
Kozakov, D. et al. How good is automated protein docking? Proteins 81,
2159–2166 (2013).

Acknowledgements
We thank all members of the Fujise laboratory for their collaborative work: Nong Gao
He, Ph.D. and Minako Oda, Ph.D., for maintaining and improving the lab environment
as Lab Managers, and Ms. Senem Aykul, a research scientist, for their assistance with
scientiﬁc experiments. The project was supported in part by grants from the National
Heart, Blood, and Lung Institute within the National Institutes of Health (HL138992,
HL152723, HL117247 to K.F.), the American Heart Association Established Investigator
Award (0540054N to K.F.), and the American Heart Association Grant-in-Aid (7770000
to K.F.). The graphics depicted in Figs. 3a, 3b, 6e, and S1b were created with
BioRender.Com.

Author contributions
K.F. conceived the general idea and framework of the project, designed the majority of
the experiments, and oversaw the project to its completion. K.R. discussed the general
ideas and hypotheses of the project with K.F. D.P. generated recombinant strep-tagfortilin and strep-tag-luciferase, performed luciferase and Smad3 phosphorylation assays
in MEF-F11 cells, designed and performed BLI experiments, ELISA assays, and coimmunoprecipitation-western blot analyses for TGF-β1. E.M.H. designed and conducted
the SPR experiments and some luciferase assays. F.M. performed coimmunoprecipitation-western blot analyses for TGF-β2 and -β3. N.R.E. performed
afﬁnity column co-puriﬁcation assays. R.S. performed Smad3 phosphorylation assays
using HEK293 cells. W.J. and S.C. performed the C3H10T1/2 cell experiments. M.D.K.
performed computer-assisted virtual docking experiments. E.M.H., R.S., D.P., and K.F.

COMMUNICATIONS BIOLOGY | (2022)5:157 | https://doi.org/10.1038/s42003-022-03112-6 | www.nature.com/commsbio

COMMUNICATIONS BIOLOGY | https://doi.org/10.1038/s42003-022-03112-6

analyzed data and composed ﬁgures. K.F. wrote the manuscript. E.M.H., K.R., D.P., S.C.,
and K.F. proofread the manuscript.

ARTICLE

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional afﬁliations.

Competing interests
The authors declare no competing interests.

Additional information
Supplementary information The online version contains supplementary material
available at https://doi.org/10.1038/s42003-022-03112-6.
Correspondence and requests for materials should be addressed to Ken Fujise.
Peer review information Communications Biology thanks the anonymous reviewers for
their contribution to the peer review of this work. Primary Handling Editors: Georgios
Giamas and Eve Rogers.
Reprints and permission information is available at http://www.nature.com/reprints

Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing,
adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative
Commons license, and indicate if changes were made. The images or other third party
material in this article are included in the article’s Creative Commons license, unless
indicated otherwise in a credit line to the material. If material is not included in the
article’s Creative Commons license and your intended use is not permitted by statutory
regulation or exceeds the permitted use, you will need to obtain permission directly from
the copyright holder. To view a copy of this license, visit http://creativecommons.org/
licenses/by/4.0/.
© The Author(s) 2022

COMMUNICATIONS BIOLOGY | (2022)5:157 | https://doi.org/10.1038/s42003-022-03112-6 | www.nature.com/commsbio

13

